Evidence map›Paper›PMID 25210194›Full record

ArticleJournal of virology2014

The HERV-K human endogenous retrovirus envelope protein antagonizes Tetherin antiviral activity.

Cécile Lemaître, Francis Harper, Gérard Pierron, Thierry Heidmann, Marie Dewannieux

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Molecular functions of human endogenous retroviruses in health and disease.Cellular and molecular life sciences : CMLS · 2015
    Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Cécile LemaîtreCNRS, UMR 8122, Institut Gustave Roussy, Villejuif, France Université Paris-Sud, Orsay, France Université Paris Denis Diderot, Sorbonne Paris-Cité, Paris, France.
Francis HarperCNRS, UMR 8122, Institut Gustave Roussy, Villejuif, France Université Paris-Sud, Orsay, France.
Gérard PierronCNRS, UMR 8122, Institut Gustave Roussy, Villejuif, France Université Paris-Sud, Orsay, France.
Thierry HeidmannCNRS, UMR 8122, Institut Gustave Roussy, Villejuif, France Université Paris-Sud, Orsay, France heidmann@igr.fr marie.dewannieux@igr.fr.
Marie DewannieuxCNRS, UMR 8122, Institut Gustave Roussy, Villejuif, France Université Paris-Sud, Orsay, France heidmann@igr.fr marie.dewannieux@igr.fr.
Université Paris-Sud · FRCentre National de la Recherche Scientifique · FRInstitut Gustave Roussy · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledEndogenous retroviruses are the remnants of past retroviral infections that are scattered within mammalian genomes. In humans, most of these elements are old degenerate sequences that have lost their coding properties. The HERV-K(HML2) family is an exception: it recently amplified in the human genome and corresponds to the most active proviruses, with some intact open reading frames and the potential to encode viral particles. Here, using a reconstructed consensus element, we show that HERV-K(HML2) proviruses are able to inhibit Tetherin, a cellular restriction factor that is active against most enveloped viruses and acts by keeping the viral particles attached to the cell surface. More precisely, we identify the Envelope protein (Env) as the viral effector active against Tetherin. Through immunoprecipitation experiments, we show that the recognition of Tetherin is mediated by the surface subunit of Env. Similar to Ebola glycoprotein, HERV-K(HML2) Env does not mediate Tetherin degradation or cell surface removal; therefore, it uses a yet-undescribed mechanism to inactivate Tetherin. We also assessed all natural complete alleles of endogenous HERV-K(HML2) Env described to date for their ability to inhibit Tetherin and found that two of them (out of six) can block Tetherin restriction. However, due to their recent amplification, HERV-K(HML2) elements are extremely polymorphic in the human population, and it is likely that individuals will not all possess the same anti-Tetherin potential. Because of Tetherin's role as a restriction factor capable of inducing innate immune responses, this could have functional consequences for individual responses to infection. IMPORTANCE: Tetherin, a cellular protein initially characterized for its role against HIV-1, has been proven to counteract numerous enveloped viruses. It blocks the release of viral particles from producer cells, keeping them tethered to the cell surface. Several viruses have developed strategies to inhibit Tetherin activity, allowing them to efficiently infect and replicate in their host. Here, we show that human HERV-K(HML2) elements, the remnants of an ancient retroviral infection, possess an anti-Tetherin activity which is mediated by the envelope protein. It is likely that this activity was an important factor that contributed to the recent, human-specific amplification of this family of elements. Also, due to their recent amplification, HERV-K(HML2) elements are highly polymorphic in the human population. Since Tetherin is a mediator of innate immunity, interindividual variations among HERV-K(HML2) Env genes may result in differences in immune responses to infection.

Indexed as

Antigens, CDBone Marrow Stromal Antigen 2Cell LineEndogenous RetrovirusesGPI-Linked ProteinsHumansImmunoprecipitationViral Envelope ProteinsAntigens, CDBone Marrow Stromal Antigen 2BST2 protein, humanGPI-Linked ProteinsViral Envelope Proteins

Identifiers

PMID25210194
PMCPMC4248984
OpenAlexW2164118809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.